Robert W. Baird Analysts Give Alexion Pharmaceuticals (ALXN) a $165.00 Price Target
Alexion Pharmaceuticals (NASDAQ:ALXN) has been given a $165.00 price target by analysts at Robert W. Baird in a research note issued on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Robert W. Baird’s price target indicates a potential upside of 27.92% from the company’s previous close.
A number of other equities analysts also recently weighed in on ALXN. Credit Suisse Group upped their target price on Alexion Pharmaceuticals from $149.00 to $154.00 and gave the company an “outperform” rating in a report on Tuesday, June 5th. BidaskClub upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 15th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $140.00 target price on the stock in a report on Tuesday, June 26th. ValuEngine downgraded Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, June 26th. Finally, Evercore ISI restated an “outperform” rating and issued a $158.00 price objective on shares of Alexion Pharmaceuticals in a report on Thursday, July 26th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $159.50.
Shares of ALXN opened at $128.99 on Monday. The stock has a market capitalization of $27.19 billion, a PE ratio of 25.00, a price-to-earnings-growth ratio of 1.17 and a beta of 0.84. Alexion Pharmaceuticals has a fifty-two week low of $102.10 and a fifty-two week high of $144.91. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.27 and a current ratio of 2.72.
In related news, CFO Paul J. Clancy sold 5,241 shares of the stock in a transaction that occurred on Tuesday, July 10th. The stock was sold at an average price of $131.11, for a total value of $687,147.51. Following the transaction, the chief financial officer now owns 93,309 shares in the company, valued at $12,233,742.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.35% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. acquired a new position in Alexion Pharmaceuticals during the first quarter valued at approximately $211,000. KBC Group NV grew its holdings in Alexion Pharmaceuticals by 36.3% during the first quarter. KBC Group NV now owns 27,492 shares of the biopharmaceutical company’s stock valued at $3,064,000 after purchasing an additional 7,316 shares during the last quarter. Gabelli Funds LLC grew its holdings in Alexion Pharmaceuticals by 38.9% during the first quarter. Gabelli Funds LLC now owns 47,500 shares of the biopharmaceutical company’s stock valued at $5,294,000 after purchasing an additional 13,300 shares during the last quarter. Toronto Dominion Bank grew its holdings in Alexion Pharmaceuticals by 24.3% during the first quarter. Toronto Dominion Bank now owns 119,616 shares of the biopharmaceutical company’s stock valued at $13,329,000 after purchasing an additional 23,394 shares during the last quarter. Finally, Brinker Capital Inc. grew its holdings in Alexion Pharmaceuticals by 20.4% during the first quarter. Brinker Capital Inc. now owns 5,685 shares of the biopharmaceutical company’s stock valued at $634,000 after purchasing an additional 962 shares during the last quarter. Hedge funds and other institutional investors own 93.02% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
See Also: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.